TCTR20150313002Enrolling By InvitationPhase 3
Intravenous N-acetyl-cysteine (NAC) Administration for Prevention of Post-embolization Syndrome in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
Faculty of Medicine, Thammasat University0 sites80 target enrollmentStarted: March 13, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Enrolling By Invitation
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •- Patients with a diagnosis of hepatocellular carcinoma (HCC) and subjected to treat with chemoembolization (TACE) ( The diagnosis of HCC is based on (American association of liver diseases (AASLD) guidelines 2010)
- •- Age 18-65 years
- •- No contraindication to N-acetyl-cysteine
Exclusion Criteria
- •- Receiving other treatment within 6 months duration (e.g. radiofrequency ablation (RFA) or surgical liver resection)
- •- Having severe underlying illness e.g. ESRD, cardiac disease, AIDS, etc.
- •- Pregnancy or lactation
- •- Receiving possible drug interaction with NAC e.g. Nitroglycerine
- •- Denial to participate the study
Investigators
Similar Trials
Completed
Phase 1
Intratympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-induced Ototoxicity: Double Blind Randomized Clinical TrialIntratympanic InjectionDexamethasoneAcetylcysteinehearing impairmentHearing LossTCTR20160314003Student Research Committee114
Not yet recruiting
Phase 2
A clinical trial to study safety and efficacy of N-Acetylcysteine (NAC)(new drug) as an adjunct to standard treatment in patients with acute ischemic strokeCTRI/2019/05/019305AIIMS New Delhi
Recruiting
Phase 3
Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgeryRenal Impairment in cardiac surgeryRenal and Urogenital - Other renal and urogenital disordersCardiovascular - Other surgeryACTRN12606000088549Prince of Wales Hospital200
Not yet recruiting
Unknown
AC for treatment of Obsessive-Compulsive DisorderObsessive-compulsive disorderObsessive-compulsive disorder.IRCT20170123032145N7Iran University of Medical Sciences44
Recruiting
Phase 1
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.Ototoxic Hearing LossNCT04291209Sunnybrook Health Sciences Centre80